211 related articles for article (PubMed ID: 24057195)
1. Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report.
Nardone B; Saddleton E; Laumann AE; Edwards BJ; Raisch DW; McKoy JM; Belknap SM; Bull C; Haryani A; Cowper SE; Abu-Alfa AK; Miller FH; Godinez-Puig V; Dharnidharka VR; West DP
Pediatr Radiol; 2014 Feb; 44(2):173-80. PubMed ID: 24057195
[TBL] [Abstract][Full Text] [Related]
2. Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.
Edwards BJ; Laumann AE; Nardone B; Miller FH; Restaino J; Raisch DW; McKoy JM; Hammel JA; Bhatt K; Bauer K; Samaras AT; Fisher MJ; Bull C; Saddleton E; Belknap SM; Thomsen HS; Kanal E; Cowper SE; Abu Alfa AK; West DP
Br J Radiol; 2014 Oct; 87(1042):20140307. PubMed ID: 25230161
[TBL] [Abstract][Full Text] [Related]
3. Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents.
Semelka RC; Prybylski JP; Ramalho M
Magn Reson Imaging; 2019 May; 58():174-178. PubMed ID: 30471330
[TBL] [Abstract][Full Text] [Related]
4. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents.
Smorodinsky E; Ansdell DS; Foster ZW; Mazhar SM; Cruite I; Wolfson T; Sugay SB; Iussich G; Shiehmorteza M; Kono Y; Kuo A; Sirlin CB
J Magn Reson Imaging; 2015 May; 41(5):1259-67. PubMed ID: 24811860
[TBL] [Abstract][Full Text] [Related]
5. Contemporary applications and limitations of magnetic resonance imaging contrast materials.
Natalin RA; Prince MR; Grossman ME; Silvers D; Landman J
J Urol; 2010 Jan; 183(1):27-33. PubMed ID: 19913804
[TBL] [Abstract][Full Text] [Related]
6. Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD?
Martin DR
Am J Kidney Dis; 2010 Sep; 56(3):427-30. PubMed ID: 20728788
[No Abstract] [Full Text] [Related]
7. Gadolinium-associated nephrogenic systemic fibrosis.
Schlaudecker JD; Bernheisel CR
Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
[TBL] [Abstract][Full Text] [Related]
8. Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration.
Yang L; Krefting I; Gorovets A; Marzella L; Kaiser J; Boucher R; Rieves D
Radiology; 2012 Oct; 265(1):248-53. PubMed ID: 22923714
[TBL] [Abstract][Full Text] [Related]
9. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration.
Kanal E; Patton TJ; Krefting I; Wang C
AJNR Am J Neuroradiol; 2020 Mar; 41(3):393-399. PubMed ID: 32115422
[TBL] [Abstract][Full Text] [Related]
11. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 2.
Thomsen HS
Acta Radiol; 2016 Jun; 57(6):643-8. PubMed ID: 26802070
[No Abstract] [Full Text] [Related]
12. Gadolinium-associated nephrogenic systemic fibrosis in a 9-year-old boy.
Foss C; Smith JK; Ortiz L; Hanevold C; Davis L
Pediatr Dermatol; 2009; 26(5):579-82. PubMed ID: 19840315
[TBL] [Abstract][Full Text] [Related]
13. Nephrogenic systemic fibrosis: clinical spectrum of disease.
Mayr M; Burkhalter F; Bongartz G
J Magn Reson Imaging; 2009 Dec; 30(6):1289-97. PubMed ID: 19937929
[TBL] [Abstract][Full Text] [Related]
14. Nephrogenic systemic fibrosis: a concise review for cardiologists.
Cheong BY; Muthupillai R
Tex Heart Inst J; 2010; 37(5):508-15. PubMed ID: 20978560
[TBL] [Abstract][Full Text] [Related]
15. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.
Kitajima K; Maeda T; Watanabe S; Ueno Y; Sugimura K
Int J Urol; 2012 Sep; 19(9):806-11. PubMed ID: 22571387
[TBL] [Abstract][Full Text] [Related]
16. Gadolinium and nephrogenic systemic fibrosis: have the alarm bells been silenced?
Tamburrini O; Balducci A
Radiol Med; 2012 Feb; 117(1):1-5. PubMed ID: 22020430
[TBL] [Abstract][Full Text] [Related]
17. Nephrogenic systemic fibrosis: a review of the new conundrum.
Goenka AH; Das CJ; Sharma R
Natl Med J India; 2009; 22(6):302-6. PubMed ID: 20384019
[TBL] [Abstract][Full Text] [Related]
18. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
[TBL] [Abstract][Full Text] [Related]
19. Nephrogenic systemic fibrosis: A survey of the use of gadolinium-based contrast agents in Ghana.
Piersson AD; Gorleku PN
Radiography (Lond); 2017 Nov; 23(4):e108-e113. PubMed ID: 28965904
[TBL] [Abstract][Full Text] [Related]
20. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents.
Penfield JG
Pediatr Nephrol; 2008 Dec; 23(12):2121-9. PubMed ID: 18543004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
